Mirabegron in the Management of Overactive Bladder Syndrome

• Published in: International journal of women's health Vol. 14; pp. 1337 - 1350
• Main Authors: O'Kane, Miriam, Robinson, Dudley, Cardozo, Linda, Wagg, Adrian, Abrams, Paul
• Format: Journal Article
• Language: English
• Published: Macclesfield Dove Medical Press Limited 01-01-2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Adrenergic receptors; Bladder; Drug dosages; Drug therapy; Females; Metabolism; Metabolites; Mirabegron; Older people; overactive bladder; Pharmacokinetics; Review; Urinary incontinence; Womens health; β3-adrenoceptor agonist; Canada; United Kingdom; Japan
• ISSN: 1179-1411; 1179-1411
• DOI: 10.2147/IJWH.S372597

Overactive bladder (OAB) negatively affects work productivity and quality of life in sufferers. Its overall impact is likely to increase as a result of increasing prevalence in an ageing population. The pathophysiology of OAB is not completely understood but the [beta]3-adrenoceptor, which is highly expressed in the urinary bladder, is thought to be important for mediating human detrusor relaxation during the storage phase. Clinical trial results have demonstrated that mirabegron, a selective [beta]3-adrenoceptor agonist offers substantial clinical efficacy and good adherence rates over 12 months. Furthermore, due to its different mechanism of action, it is likely to offer a favourable tolerability profile when compared with antimuscarinic agents, resulting in improved persistence over long-term treatment. Finally, from a health economic perspective, despite its higher drug acquisition cost, mirabegron has been found to be cost- effective, owing to the greater increase in quality-adjusted-life-years gained, when compared to antimuscarinic medications. The PubMed database was searched for English language articles published between 1 January 2005 to 31 January 2022, on the subject of mirabegron. Search terms included "mirabegron", "overactive bladder", "[beta]3-adrenoceptor agonist", "urinary incontinence". This review summarises the evidence for mirabegron as a treatment option for the management of OAB. Keywords: [beta]3-adrenoceptor agonist, drug therapy, mirabegron, overactive bladder, urinary incontinence